Dr. Rui Guo 郭蕊
Chief Physician
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for head and neck tumors, with a focus on radiation and comprehensive treatment for nasopharyngeal carcinoma.
Dr. Guo is a Chief Physician and master’s supervisor at Sun Yat-sen University Cancer Center. Dr. Guo earned a doctorate in oncology from Sun Yat-sen University in 2015. Research focuses on nasopharyngeal carcinoma prevention, diagnosis, and treatment, including staging, new radiation technologies, prognosis evaluation, and molecular mechanisms.
Professional roles
- Standing Committee Member, Nasopharyngeal Carcinoma Professional Committee, China Health Promotion Association
- Member, Nutrition Group, Radiation Oncology Branch, Chinese Medical Association
- Member, Youth Committee of the Nasopharyngeal Carcinoma Professional Committee, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (Guo Rui). Papers usually list the name as Rui Guo or Guo R.
Selected publications
121 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Death Differ, 2026 (senior author): USP18 promotes nasopharyngeal carcinoma radioresistance via TRIM29 oligomerization and ubiquitination. PubMed 41219493
- Int J Radiat Oncol Biol Phys, 2025 (first author): Long-term Outcomes Following Individualized Primary Tumor Clinical Target Volume Delineation Based on Stepwise Spread Patterns of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy. PubMed 39701547
- Radiother Oncol, 2024 (senior author): Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'". PubMed 38740090
- Radiother Oncol, 2024 (senior author): Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study. PubMed 38432309
- JAMA, 2023 (first author): Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma-Reply. PubMed 36648471
- Nat Microbiol, 2022 (first author): Author Correction: DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. PubMed 35505195
- Clin Transl Med, 2020 (first author): New parameters of the 8th edition AJCC/UICC T category in nasopharyngeal carcinoma: Cervical vertebrae invasion and parotid gland invasion. PubMed 33252857
- Nat Microbiol, 2020 (first author): DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. PubMed 32424339
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion